← boardnext 2026-10next 2026-11-30next 2028-03
IMCR
Immunocore Ltddistress 1/10 · well-funded / low risk$35.10-1%today-13% from 52w high
Lead: Advanced Melanoma · est. market ~$10B (approx, global)
Revenue
$107M
Liquidity
$845M
Runway
33.9 yrs
Shares 1y
+1%
Price & events
+0.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.2%
1D
+1.8%
1W
+20.2%
1M
+20.1%
3M
-0.0%
6M
-2.6%
1Y
-10.5%
2Y
+1.6%
5Y
-18.8%
All
Overview
- Market Cap
- $1.79B
- Volume
- 17.81K
- 52 Week Range
- $27.79 – $40.22
- Total Shares
- 50.87M
- Float Shares
- 42.46M
- Short %
- 19.67%
- % Held by Insiders
- 0.07%
- % Held by Institutions
- 104.65%
- RVOL
- 0.03x
- Beta
- 0.73
Pipeline stages · 3 programs
Brenetafusp, Nivolumab, Relatlimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IMC-P115C
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10 Estimated 50% readout ~2026-11-15 | Phase 1/2 | Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy | Select Advanced Solid Tumors | — | active not recruiting |
| 2026-11-30 Estimated 50% readout ~2027-01-14 | Phase 1/2 | IMC-R117C, Chemotherapy drug, Kinase inhibitor | Cancer, HLA-A*02:01-positive | — | recruiting |
| 2027-09-30 Estimated 50% readout ~2027-10-30 | Phase 1 | IMC-P115C | PRAME Positive, Cancer, HLA-A*02:01-positive | — | recruiting |
| 2027-10-16 Estimated 50% readout ~2027-12-30 | Phase 3 | Brenetafusp, Nivolumab, Relatlimab | Advanced Melanoma | — | recruiting |
| 2028-03 Estimated 50% readout ~2028-05-15 | Phase 3 | Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice | Advanced Melanoma | — | recruiting |
Catalyst news & presentations · 16
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)IMC-U120AI · Submit clinical trial application for second autoimmune candidateSEC 8-K
- 2026Guided 40%readoutPhase 3KIMMTRAK · Topline results for TEBE-AM trial in second-line cutaneous melanomaSEC 8-K
- second half of 2026Guided 55%conferencedata presentationsecondaryPhase 1IMC-P115C · Initial data from Phase 1 trial of PRAME-A02-HLE candidateSEC 8-K
- as early as second half of 2026Guided 55%readoutPhase 3tebentafusp · Topline data from Phase 3 TEBE-AM trialSEC 8-K
- second half of 2026Guided 55%conferencedata presentationsecondaryPhase 1/2brenetafusp · Present data from Phase 1/2 brenetafusp combinations in ovarian cancerSEC 8-K
- second half of 2026Guided 55%conferencedata presentationsecondaryPhase 1Additional data from Phase 1 HIV trialSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 1IMC-S118AI · Dose first patient in Phase 1 type 1 diabetes trialSEC 8-K
- first half of 2026readoutPhase 3tebentafusp · Long-term 5-year overall survival data from Phase 3 mUM trialSEC 8-K
- first half of 2026enrollment completesecondaryPhase 3tebentafusp · Complete enrollment of Phase 3 TEBE-AM trialSEC 8-K
- January 14, 2026conferencedata presentationsecondaryCorporate presentation at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- year end 2025regulatory submissionFiled (NDA/BLA)IMC-S118AI · CTA submission for autoimmune candidate targeting PPI x PD1SEC 8-K
- first quarter 2025readoutPhase 1IMC-M113V · Initial multiple ascending dose data for HIV TCR therapySEC 8-K
- September 16, 2024conferencedata presentationsecondaryPhase 1/2KIMMTRAK, brenetafusp · Oral presentation of translational data showing T cell fitness signature association with clinical activitySEC 8-K
- September 14, 2024conferencedata presentationsecondaryPhase 1brenetafusp · Presented Phase 1 monotherapy and chemotherapy combination dataSEC 8-K
- 2024-08-28withdrawalCFO Brian Di Donato notified resignation effective Dec 31, 2024.SEC 8-K
Approved drugs (1)
- KIMMTRAKTEBENTAFUSP-TEBN2022 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $63 (+81% upside) · 12 analysts
- 2026-04-20HC Wainwright & Co.Buy
- 2026-04-14HC Wainwright & Co.Buy
- 2026-03-16JefferiesBuy → Hold
- 2026-02-26NeedhamBuy
- 2026-02-04HC Wainwright & Co.Buy
- 2025-11-10Morgan StanleyEqual-Weight
Competitors — Advanced Melanoma
Recent news
- 2026-07-21Immunocore Holdings Plc (IMCR): Investor Outlook And 86% Potential Upside - DirectorsTalk Interviews
- 2026-07-20IRGC, IMCR, GRU designated threat to national security - Counter Terror Business
- 2026-07-19(IMCR) Volatility Zones as Tactical Triggers - Stock Traders Daily
- 2026-07-13Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh - TradingView
- 2026-07-13UK government moves to ban Iran’s IRGC, Russia’s GRU volunteer corps and IMCR - Межа. Новини України.
- 2026-07-13UK designates IRGC, IMCR and Russian GRU Volunteer Corps under new state threats powers - Business Upturn
- 2026-07-13UK bans Iran’s IRGC, IMCR after attacks on Jewish sites - Crypto Briefing
- 2026-07-13UK GOVERNMENT: DESIGNATION COMES AFTER THE IMCR HAVE PUBLICLY CLAIMED SEVEN ATTACKS AT UK LOCATIONS LINKED TO JEWISH AND ISRAELI COMMUNITIES - news.cgtn.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.